# Artificial intelligence-driven antimicrobial peptide discovery

Paulina Szymczak<sup>a</sup>, Ewa Szczurek<sup>a,\*</sup>

<sup>a</sup>Faculty of Mathematics, Informatics and Mechanics, University of Warsaw, Banacha 2, 02-097, Warsaw, Poland

#### Abstract

Antimicrobial peptides (AMPs) emerge as promising agents against antimicrobial resistance, providing an alternative to conventional antibiotics. Artificial intelligence (AI) revolutionized AMP discovery through both discrimination and generation approaches. The discriminators aid the identification of promising candidates by predicting key peptide properties such as activity and toxicity, while the generators learn the distribution over peptides and enable sampling novel AMP candidates, either *de novo*, or as analogues of a prototype peptide. Moreover, the controlled generation of AMPs with desired properties is achieved by discriminator-guided filtering, positive-only learning, latent space sampling, as well as conditional and optimized generation. Here we review recent achievements in AI-driven AMP discovery, highlighting the most exciting directions.

## Introduction

Antimicrobial resistance, fueled by antibiotic overuse that drives the emergence of resistant strains, is recognized as a global health hazard. It was ranked the third cause of death in 2019, exceeding HIV and malaria [1]. With no successful novel antibiotics developed for over 30 years [2], there is a pressing need for discovering new antimicrobial pharmaceuticals. Antimicrobial peptides (AMPs) are an appealing alternative to known antibiotics [1]. Innate to host defense systems, they combat antibiotic-resistant pathogens, with slower resistance emergence than conventional antibiotics [3]. Despite extensive research, so far only 77 AMPs were in trials [4], none serve as clinical antibiotics and only 11 were commercialized [5]. Clinical failures result from low activity, high toxicity, or instability, motivating efforts in designing safer, more effective AMPs [6].

Recent years witnessed a tremendous advancement in AI, in particular the development of generative and large language models, revolutionizing the design of drugs [7], proteins [8] as well as AMPs [9, 10, 11, 12]. Since the most recent reviews on AI-driven AMP discovery either cover the principles of the specific AI methods, including language and generative models [12], or focus on geometric deep learning methods [11], here we complement the review of approaches spanning the last two years, highlighting the most exciting directions.

We provide a detailed characterization of tasks that the AI methods can perform in AMP discovery, introducing the diverse properties of AMPs, and their model representations. We discuss two main categories of AI methods with crucial importance for AMP design: *discrimination* and *generation* (Figure 1a). We group the most recent discriminators by the predicted properties and categorize the emerging generators by the mode of *unconstrained* and *analogue* generation (Figure 1b). We further discuss approaches to controlled generation of peptides with desired properties (Figure 1c). Moreover, we summarise approaches to evaluation of AMP discovery, both from the methodological and experimental side. Finally, we outline unaddressed challenges impeding AMP delivery to the clinic, highlighting the methodological opportunities for advancement.

# State of the art

## AMPs are characterized by various properties

AMPs are short (10–100 amino acids) peptides that possess an overall positive charge (typically +2 to +9) and a large percentage ( $\geq 30\%$ ) of hydrophobic amino acids. Although positively charged AMPs preferentially target microbial membranes, some are toxic to mammalian cells. AMPs are characterized by various

<sup>\*</sup>Corresponding author

Email addresses: p.szymczak8@uw.edu.pl (Paulina Szymczak), szczurek@mimuw.edu.pl (Ewa Szczurek)



Figure 1: **AI-driven AMP discovery. a** AMP discovery overview, including AMP properties of interest, main AI methods, and evaluation. The arrow indicates the relevance of evaluation approaches. **b** AMP generation modes: unconstrained and analogue. In the analogue mode, single step or more steps can be performed, with the latter yielding less similar, but potentially more optimized peptides. **c** Controlled AMP generation, including: discriminator-guided filtering, positive-only learning, latent space sampling, conditional and optimized generation. Circles represent peptides. The shades of green and red indicate activity and inactivity, respectively. The size of circles are indicative of diverse structural properties e.g. length, secondary structure.

properties, each informative of its clinical potential (Figure 1a), including activity, toxicity, stability, and synergy. First, activity is measured in antimicrobial assays against various bacterial strains as Minimum Inhibitory Concentration (MIC) or Minimal Bacterial Concentration (MBC). Common reference strains include *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 25923, with fewer assays incorporating drug-resistant strains. Assays generally adhere to the MIC/MBC protocol outlined by Clinical and Laboratory Standards Institute (CLSI) [13]. However, they do vary in bacterial concentration and medium usage, potentially introducing bias for CFU levels above  $5 \times 10^5$  cells/mL due to the inoculum effect [14].

Peptide toxicity is typically measured either as hemolytic activity or cytotoxicity. Hemolysis is mainly evaluated using HC50, indicating the peptide concentration causing 50% hemolysis in human erythrocytes. Other mammals' erythrocytes, like rabbits or sheep, are also used. Cytotoxicity is examined across diverse cell types (fibroblast, colon, lung, cancer lines) using IC50, EC50, or 50% cell death.

Numerous databases record activity and toxicity measurements, along with sequence and structure [15]. While all databases allow manual browsing, DBAASP [16] is the only resource with an Application Programming Interface, facilitating automatic extraction of specific peptide information in desired format. Additionally, DBAASP records medium and CFU data for each activity entry, along with synergistic effects between antimicrobial peptides, conventional antibiotics, and other agents. Synergy is expressed as the Fractional Inhibition Concentration (FIC) index, where FIC values  $\leq 0.5$  denote significant synergy.

Ref	Task	Property	Positive	Negative		
		Activity	Active	Inactive		
[35]	Discriminaton		MIC $<25 \ \mu g/ml$	$MIC > 100 \ \mu g/ml$		
[34]	Discrimination		MIC $<25 \ \mu g/ml$	MIC >100 $\mu$ g/ml		
[20]	Generation		MIC $<25 \ \mu g/ml$	$MIC > 100 \ \mu g/ml$		
[42]	Generation		MIC $<5 \mu M$	$MIC > 5 \mu M$		
[31]	Generation		MIC $<32 \ \mu g/mL$	$MIC > 32 \ \mu g/mL$		
[28]	Generation		MIC $<32 \ \mu g/mL$ or $10 \ \mu M$	MIC $>$ 32 $\mu$ g/mL or 10 $\mu$ M		
[24]	Generation		$\log MIC < 4 \mu M$	$\log MIC > 4 \mu M$		
		Toxicity	Non-toxic	Toxic		
[28]	Generation		Less than 20% hemolysis at a concentration of at least 50 $\mu\mathrm{M}$	more than $20\%$ hemolysis at any concentration		
[23]	Discriminaton		$HC50 > 100 \ \mu g/ml$	$HC50 < 100 \ \mu g/ml$		
[52]	Discriminaton		$HC50 > 100 \ \mu g/ml$	$HC50 < 100 \ \mu g/ml$		
[42]	Generation		$\rm HC50 > 100 \ \mu M$	$\rm HC50 < 100 \ \mu M$		
[33]	Discrimination		$MHC \ge 50 \ \mu M$	$MHC \le 50 \ \mu M$		
[20]	Generation		Hemolytic/cytotoxic activities >250 $\mu {\rm g/ml}$	Hemolytic/cytotoxic activities ${<}200~\mu{\rm g/ml}$		

Table 1: Activity and toxicity thresholds applied in AMP discovery methods used for defining positive and negative examples.

# Different AI approaches differ by the way AMPs are represented and provided at their input for training

The most prevalent AMP representation based on the amino acid code is simply its sequence [17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32]. Interestingly, despite the clear influence of N and C-terminal modifications on peptide structure and charge, only a limited number of methods have incorporated this information into their design [33, 25]. Beyond sequence, derived AMP properties like amino acid composition, physicochemical attributes [34, 35, 36, 37, 38, 39], sequence similarity [40], and structural details like secondary structure [41], molecular fingerprints [42], and atom-type connectivity [43] are also used. Pretrained language model-derived sequence embeddings have recently proven effective for AMP discovery [44, 45, 46, 47, 48, 49, 50, 51]. Some methods employ combinations of these encodings [40, 33, 52].

Most AI-driven AMP discovery methods operate in a supervised setting, with positive and negative datasets used for training. However, each study defines these sets differently. First, the positive examples often constitute the whole collection of peptides from AMP databases, regardless of their target species or strain. This introduces on the one hand large heterogeneity of the positive samples and a bias on the other, as for bacterial AMPs, most of them were tested solely against *E. coli*. The negative datasets are frequently sampled from UniProt, excluding entries matching keywords such as antimicrobial, antibiotic, secreted, and similar [17, 44, 37, 40, 49, 19, 41, 24, 50]. Yet, Sidorczuk et al. [53] demonstrated that such negative data selection is highly biased by the sampling methods. Alternatively, Porto *et al.* [39] suggested using shuffled AMP sequences as negatives.

A more nuanced approach involves considering activity or toxicity for positive/negative dataset definition, but constructing such datasets is obscured by conflicts in units and contradictory entries in databases. First, activity measurements are reported in weight/volume ( $\mu$ g/mL) or molarity ( $\mu$ M), and no consensus exists on the preferred unit system due to the absence of guidelines from CLSI. Converting measurements to uniform units during data collection is common, but often overlooks the counterion content's influence on antimicrobial peptide activity and cytotoxicity [54]. Second, one peptide can be reported with varied activity/toxicity measures against the same strain/cell type by different labs. Common approaches of resolving potential conflicts among multiple entries include averaging per strain/genera [21, 25, 46, 36], decile discretization [21], selecting minimal reported value, discarding conflicting entries [34], or retaining all measurements despite conflicts [52, 23]. Yet, consensus is lacking on what constitutes an active or toxic peptide, with different methods assuming different thresholds (Table 1).

# Artificial intelligence approaches for AMP discovery are dominated by discriminators and generative models

Two primary AI-driven tasks for AMP discovery are discrimination and generation (Figure 1a). We begin by describing models in the discrimination category.

#### AMP discriminators

The field is flooded with methods that classify peptides broadly as either AMP or non-AMP. Recent approaches of this type, such as AMPlify [17], a bidirectional long short-term memory (LSTM) model with

additional multihead attention mechanism, or AMP-BERT [44], a BERT model pretrained on protein sequences, predominantly use deep learning to automatically derive descriptive features for classification. VGG16-AMP [43] converts sequence and structure information into a 3-channel image based on connectivity matrices, enabling the application of image recognition methods. Antimicrobial peptides are further subcategorized into antibacterial, antiviral, antifungal, anticancer (and more). While some methods classify AMPs into specific subcategories like anticancer peptides in a binary fashion [55], recent approaches tackle the challenging multi-label classification, hindered by limited training data [49, 40]. For example, Yang et al. [40] propose a two-stage binary classification: first into AMP/non-AMP categories, and second, antimicrobial/non-antimicrobial subcategories. Notably, in these basic classification tasks, hand-engineered descriptor-based methods, offer competitive performance compared to deep learning approaches [39]. However, AMP or AMP subcategory classification, addressed by numerous studies, lacks specificity and utility for AI-driven AMP discovery. Peptides classified as AMPs might not exhibit high activity against specific bacterial strains, as indicated by our evaluation [31].

MIC prediction methods have the potential to give more specific and practically applicable predictions. MIC prediction is framed either as regression, yielding MIC values [36, 46], or as classification, discerning active from inactive peptides [34, 35] using a set threshold. Depending on the dataset construction, the MIC prediction methods provide predictions for specific genera [25, 46], species [34], or strain [35]. More general, methods for microbial specific strain (MSS) prediction [35, 46] predict activity for a given peptide-bacterial strain pair. These approaches leverage the genomic information of the strain, including inter-strain similarity as well as oligonucleotide composition. Losin and Veltri introduced an approach for activity comparison [25], devising a model employing Siamese neural networks, which predicts the difference in MIC for each AMP pair. Finally, Olcay et al. [38] proposed a method which predicts synergistic effects as FIC for a peptide and an antibiotic against a given bacterial strain.

Compared to AMP and activity, much fewer discriminators for other properties were developed. In particular, classifiers of peptides either as toxic/non-toxic or hemolytic/non-hemolytic were proposed [47, 33, 52, 23]. In a recent study, Salem et al. [47] used transfer learning, first teaching a large language model to recognize secretory peptides, and then applying such model to hemolytic activity classification. AI is used as well to predict the solubility of peptides [52, 56, 57]. However, those methods are applied to longer sequences and may not be as accurate for shorter peptides. Finally, a recent secondary structure classifier tailored for short peptide sequences was built upon a combination of a pretrained language model, hypergraph multihead attention network, and bi-LSTM with conditional random fields (CRF) [48]. Apart from structure classification, structure prediction was also applied to AMPs [58, 24], although our evaluation indicated that it tends to overly stable secondary structures [31]. Similarly as in case of solubility, most of the available models for structure prediction focus on large proteins and might not be suitable for AMPs.

#### AMP generators

One traditional way of discovering AMPs was to scan a given database of peptides using discriminators. Similar approaches are still explored today, for example via an exhaustive screen of large peptide libraries [27], or by mining peptides from metagenomic data [50]. However, most recent studies aim to leverage generative AI for AMP discovery (Table 2). In unconstrained generation, peptides are freely sampled from the model *de novo* [31, 29, 28, 26, 18, 24, 21, 41, 20, 19]. In contrast, analogue generation takes a given peptide as a prototype and generates its analogues [31, 30, 22, 42, 32, 59, 51]. Analogue generation can proceed in a single or several steps, with more steps yielding peptides that are potentially more optimized but less similar to the prototype.

From the modeling framework perspective, the most popular approaches to AMP generation are GANs [19, 21, 45, 29] and VAEs [41, 24, 18, 22, 59, 30, 32, 31]. The unconstrained generation mode is implemented by all GAN-based models, but also Recurrent Neural Network (RNN) [28], and Graph Neural Network (GNN) [26], as well as all VAE models [20, 41, 24, 31]. The analogue generation task is performed solely using VAEs [30, 22, 31, 59, 32, 60], where it is possible to encode the prototype peptide and obtain its analogues through sampling process in the latent space.

In order to obtain peptides with desired AMP properties it is essential to control the generation process with respect to these properties (Figure 1c). The controlled properties of peptides include AMP [20, 45, 31, 22, 60], activity [29, 19, 20, 21, 24, 28, 31, 61, 59, 32], toxicity [20, 28, 59, 32], microbial target [19, 21], target mechanism [19, 21], hydrophobicity [22], secondary structure [41, 26, 20], as well as sequence length [19, 21].

The controlled AMP generation is obtained by approaches including discriminator-guided filtering, positiveonly learning, latent space sampling, conditional generation and optimized generation (Figure 1c).

First, in discriminator-guided filtering, the generative models are coupled with discriminators [20, 24, 45, 28] to select peptides with desired properties. Most often such discriminators are trained on the independent training set and applied on the generated samples. In CLaSS [20], the discriminators were trained in the latent space of the generative model in a rejection sampling scheme.

Positive-only learning is predominantly implemented by Generative Adversarial Networks (GANs) [29, 45] and corresponds to training exclusively on positive examples. Since these models learn the underlying data distribution, we can expect that the generated peptides will also be positive. For example, PandoraGAN was trained on experimentally validated peptides with high antiviral activity [29]. Positive-only learning was also combined with transfer learning, with recurrent neural network (RNN) model first trained on active peptides and later fine-tuned using active and non-hemolytic peptides [28].

Latent space sampling is performed by generative models equipped with the latent space, leveraging the structure of this space to sample candidates with desired properties [41, 30, 22]. For example, in PepVAE [30] active peptides were sampled from latent space regions which are most distant in terms of cosine similarity to an inactive query peptide. In turn, Renaud et al. [22] introduced PCA property aligned sampling, where by fixing a principal component of interest (e.g. identified as correlated with hydrophobicity) it is possible to generate similar peptides by sampling nearby points along other principal components. Finally, Wang et al. [41] encoded information on both the sequence and structure in the same discrete latent space of multi-scale vector quantized-VAE, which allowed generation of peptides with desired structure.

Conditional generation models are equipped with additional variables encoding for conditions corresponding to selected AMP properties, and trained to generate samples satisfying these conditions. Conditional generators include GAN-based [19, 21] and GNN [26] models. We have recently proposed HydrAMP [31], an extended conditional VAE, coupled with a pair of classifiers. Because HydrAMP was trained to perform analogue generation in temperature-controlled setting, it was possible to generate highly active analogues of a peptide without any antimicrobial activity. Morevoer, HydrAMP is the only model capable of both unconstrained and analogue generation.

Finally, optimized generation models aim to modify a given query peptide towards improved properties [32, 60]. State-of-the-art optimization algorithms were applied for AMP design, such as Bayesian optimization [42] or multi-objective evolutionary algorithm [51]. However, emerging AI-driven approaches combine generative models with optimization steps. For example, Hoffman et al. [59] introduced a VAE-based model with gradient descent zeroth-order optimization to convert a toxic peptide into a non-toxic one, while maintaining antimicrobial properties. In binary VAE [32] each peptide was scored by a distance from the Pareto front via non-dominated sorting, which was followed by optimize easily calculable properties, such as charge, density, instability index, and Boman index. Finally, Jain et al. [60] proposed an active learning algorithm leveraging epistemic uncertainty estimation and GFlowNets as a generator of a diverse batch of candidates for active peptides.

## Evaluation

For a thorough assessment of the utility of an AI method in AMP design tasks, informative evaluation measures are vital. In the case of discriminative models, standard evaluation metrics such as area under the curve (AUROC) for classifiers or root mean squared error (RMSE) for regressors are commonly used. However, there is no SOTA method that each new method would be compared to. Moreover, due to the fact that every discriminative model is trained on a different dataset regarding activity thresholds, similarity cut-offs, construction of the negative dataset etc., each model should be re-trained on the same dataset for the sake of comparison.

Compared to the discriminators, the evaluation of generation methods is generally much trickier [62]. In case of AMPs, the additional difficulty stems from the fact that every method is trained on a different dataset and targets different peptide features and that these features are hard to estimate or predict computationally.

Diversity is a basic criterion for assessing generative models, reflecting their ability to produce distinct samples from both each other and training data [60]. Common metrics for quantifying diversity in AMP generators are Levehnstein distance [41, 28, 31], BLEU [18], Jaccard similarity [22], as well as pairwise sequence similarity score [20, 59, 22, 24]. However, Liu et al. [51] criticize both Levehnstein and Jaccard

Reference	Generation mode	Generation framework	Controlled condition	Discriminators	Approach to controlled generation	Experimental validation	MD	Details
[29]	Unconstrained	GAN	Antiviral activity		Positive-only learning	no	no	
[45]	Unconstrained	GAN	AMP	yes	Discriminator-guided filtering	yes	yes	
[21]	Unconstrained	Bidirectional cGAN	Sequence length, microbial target, target mechanism, activity		Conditional generation	no	no	
[19]	Unconstrained	Bidirectional Wasserstein cGAN with gradient penalty	Sequence length, microbial target, target mechanism, activity		Conditional generation	yes	yes	
[28]	Unconstrained	RNN	Activity, toxicity	yes	Positive-only learning, Discriminator-guided filtering	yes	no	
[26]	Unconstrained	Multitask autoregressive transformer GNN	Secondary structure		Conditional generation	no	no	Forward and inverse training
[24]	Unconstrained	VAE	Activity	yes	Discriminator-guided	yes	yes	Cell-free biosynthesis
[20]	Unconstrained	Wasserstein autoencoder	AMP, activity, toxicity, structure	yes	Discriminator-guided filtering	yes	yes	Classifiers trained in the latent space
[41]	Unconstrained	Vector quantized VAE	Secondary structure		Latent space sampling	yes	no	Discrete latent space
[31]	Unconstrained, analogue	cVAE	AMP, activity	yes	Conditional generation	yes	yes	Temperature controlled creativity
[30]	Analogue	VAE	Activity		Latent space sampling	yes	no	Sampling based on cosine similarity
[22]	Analogue	VAE-like models (RNN, RNN with attention, Wasserstein autoencoder, adversarial autoencoder, transformer)	AMP, hydrophobicity		Latent space sampling	no	no	PCA property aligned sampling
[59]	Analogue	VAE	Activity, toxicity	yes	Optimized generation	no	no	Zeroth-order optimization, gradient descent
[32]	Analogue	Binary VAE	Activity, toxicity	yes	Optimized generation	yes	no	D-wave quantum annealer, non-dominated sorting, factorization machine
[60]	Analogue	GFlowNets	AMP	yes	Optimized generation	no	no	Active learning, epistemic uncertainty

Table 2: An overview of generation methods applied in AMP discovery. The table summarises the generation mode, modeling framework, the controlled conditions, the usage of discriminators, the approach to controlled generation, as well as whether experimental validation, and MD simulations in the presence of membrane were carried out. The rows marked in bold indicate methods of special and outstanding interest.

metrics for ignoring the order of amino acids and propose their own metric based on common amino acids and shared subsequences between peptides.

The specific subclass of latent space-based generative models is evaluated with respect to reconstruction ability, interpretability, as well as organization of the latent space [22].

For AMP design, generating samples with specific desired properties (e.g., high AMP probability, activity, and low toxicity) is more important than their diversity. With this respect, generative models are evaluated by applying discriminators on the generated peptide sequences and using their predictions as proxies of the true properties [20, 24, 45, 28]. Here, the limited accuracy of the existing discriminators may bias or provide overly optimistic evaluation. In contrast to AMP properties, physicochemical properties like amphipathicity, hydrophobicity, and charge are easier to compute but less specific indicators of desired features for peptide sequences.

Molecular dynamics (MD) simulations have the potential to deliver more reliable evaluation measures, at the cost of high simulation time and were used for evaluation of some of the generators (Table 2). MD was used to study both the stability of the secondary structure [45], and the mode of action of peptides [28]. Recently, MD simulations emerged as a proxy of interaction with bacterial membrane, with scores assigned to each sequence [19, 31]. MD was also used to investigate AMP preference of bacterial over human membrane [24]. These approaches were all based on computationally-heavy fully atomistic simulations. An alternative might be coarse grained simulations, which are much faster, at the price of specificity drop [20].

The ultimate evaluation of generated peptides should be performed in an experimental setting, where activity (MIC), toxicity (HC50) and other peptide features are measured on target bacteria or cell lines. Not all published generators were validated experimentally (Table 2). Since there is no consensus on MIC

thresholds (see Table 1), we proposed to summarize experimental activity validation using an AMP success rate curve instead of a single value [31]. The AMP success rate curve displays the fraction of active peptides among all experimentally tested ones, as a function of the activity threshold. Crucially, the clinical potential of peptides is best assessed at low thresholds, e.g., MIC  $\leq 2 \mu g/mL$  or  $1 \mu M$ , akin to market antibiotics. Only few generative models report such high activity of their generated peptides [31, 24, 30]. Once promising peptides are identified in initial screening of their activity and toxicity, more in depth experimental characterization should follow. This should include antimicrobial assays against drug resistant strains, cytotoxicity on cell lines, membrane disruption, time killing, resistance induction, biofilm efficacy and others.

# Challenges and opportunities

Despite recent achievements in AI-driven AMP design, significant challenges still obscure discovery of clinically-relevant AMPs. These challenges offer prospects for field advancement, on the experimental, data collection and on the methodological side.

*Construction of community-wide accepted benchmarking data.* Antibacterial or hemolytic activity datasets should be carefully compiled from already existing, publicly available databases and include both positive AMP sequences that are active against given species of bacteria, as well as of negative (inactive) peptides. The construction of such datasets would require a series of pre-processing steps that would be acceptable to the entire research community, such as computing reasonable summary measures of activity, choosing a consensus activity threshold, and recording experimental conditions in detail, such as medium, pH, or salt content. Common use of clean, large benchmarking datasets, combined with open sharing of code, would foster reproducible method training and comparability.

Filling the current gaps of knowledge to enable novel method development. Data on multiple AMP properties, such as cytotoxicity, solubility, time to resistance, stability, or degradation are either very rare or not present in databases at all. Activity measurements of clinical importance, such as MIC for carbapenem-resistant Klebsiella pneumoniae, Clostridium difficile, Mycobacterium tuberculosis, or New Delhi metallo- $\beta$ -lactamaseproducing strains, are most often not reported for the known AMPs. With MIC measurements against multiple strains, including those of clinical importance, a new type of generators could be developed that would be trained not only on AMP sequences but also on the bacterial genotypes in a multi-task manner, thereby boosting the size of the training set and bringing the functionality of the generator to a higher level. Although cytotoxicity data against different cell lines is already collected in DBAASP, it should be enlarged and extended to alternative toxicity measures, such as nephrotoxicity and leucotoxicity. The acquisition of data on such alternatives would enable development of AI methods for accurately predicting or generating non-toxic peptides. Currently, lipopeptides [63], glycopeptides [63], and peptoids [64] or peptides modified using non-proteinogenic amino acids (NPAA) and retro amino acids are investigated as alternative to traditional peptides, but constitute only a minuscule fraction of database entries. Although first methods tailored to design peptides with NPAA [42] were already proposed, further effort in this direction is needed to discover AMPs resistant to proteolytic degradation. Moreover, the extreme scarcity of data prevented development of reliable discriminators, and blocked development of anticancer AMP generators. To address the data scarcity issues and prompt AI-driven AMP discovery, coordinated effort of large-scale initiatives would be required to systematically measure and report the data, akin to the Community for Open Antimicrobial Drug Discovery.

Accounting for noise and scarcity of the data. In addition to data collection methods, equal emphasis should be laid on explicit modeling or correcting for the data noise and scarcity. While recent discriminators did attempt to tackle the data scarcity problem by transfer learning [44, 46, 47, 48, 49, 51], this problem has not been explicitly addressed by any of the AMP generation methods. Both discriminators and generators should incorporate model uncertainty measures to guide users in leveraging predictions or samples effectively.

*Exploiting clustering of known AMPs.* The antimicrobial peptide population exhibits notable similarity, as new antimicrobial peptides were frequently discovered by manipulating known AMPs, e.g. via substitution of certain amino acids or cropping longer peptides to desired length. So far treated as redundant, the existence of matched pairs of original peptides and their synthetic analogues, opens up several modeling opportunities. First, models should leverage such similar pairs to learn the hard task of discriminating between peptides

that are similar yet differ in activity, such as Brevinin-2 related peptide (MIC against *E. coli* ATCC 25726 = 20  $\mu$ M) and its analogue B2RP [K16L] which is five times weaker (MIC *E. coli* ATCC 25726 = 100  $\mu$ M), despite only one amino acid difference in sequence. In fact, filtering the similar peptides from the dataset overly simplifies the discrimination problem. Second, matched pairs should benefit the development of models for AMP comparison such as [25], where two AMPs can be ordered by their property of interest. Finally, the clustering of peptides in the training data could be accounted for by generation methods, either by grouping peptide representations from the same cluster in the latent space, or attempting cluster-dependent, local organization of the latent.

Ranking of generated AMPs. There is a dire need of approaches that rank the designed AMP sequences. Every generator can output thousands of sequences of novel AMP candidates, and only a limited number of those can be experimentally tested. Ideally, the candidates should be ranked by their chances of experimental validation. This could be approached by applying existing discriminators to predict AMP properties for each candidate. However, many discriminative methods do not output a prediction score that could be used to rank the peptides, and many peptides rank similarly high according to the available scores. We have previously applied a conservative ensemble approach to filter and rank candidates based on predictions from multiple discriminators [31]. However, systematic, dedicated ensemble method development, both for ranking in terms of activity against different strains of bacteria, and toxicity, is still missing.

AI-driven, faster and more specific molecular dynamics simulation methods. Another promising, but currently both time and computationally expensive direction in evaluating the quality of designed candidate AMP sequences is using fully atomistic simulations in the presence of bacterial or erythrocyte membrane. Here, AI could be leveraged to speed-up the molecular dynamics simulations, e.g. by predicting some simulation steps that effectively could be skipped. Similarly, AI-driven predictions of peptide conformation in the presence of a cellular membrane could be used to develop more accurate discriminators and generators.

Optimized generation methods of the future. Despite the recent emergence of several optimized AMP generation methods [60, 32, 59], this area has huge potential for future development. First, there exist no AI model that would be simultaneously trained in the task of both generation and optimization. Such a model would have the chance to exceed the optimisation capacity of current models, which so far were not able to design AMPs that would bear properties significantly better than known AMPs in the training set. Only such AMPs have the potential to make their way to the clinic and replace current antibiotics. Moreover, since each peptide should be optimized in not one, but several properties, e.g. be simultaneously active and non-toxic, more effort should be invested in Pareto optimization approaches to AMP generation. Here, methods need to account for the fact that increasing the activity and decreasing the toxicity of a peptide are in a way conflicting goals. Finally, the optimized generation methods should account for a phenomenon that could be referred to as the *idealism-realism tradeoff*. Namely, in the optimization process, the generated sequences should exceed the training samples in terms of their properties, but at the same time stay close to the training data, to remain biologically meaningful. The control of the tradeoff could be backed by additional estimators of peptide realism, e.g. by estimating relative ease of solid-state peptide synthesis using Milton Coupling Efficiency [52].

AI-driven, accelerated, automated lab and design process. Ultimately, the entire process of generating novel candidates, peptide synthesis, experimental validation in multiple parallel assays could be fully automated, and applied in an iterative, large-scale manner, potentially allowing for adaptive on-line improvement of both robots and AI methods. A rapid method of VAE-based generation and fast cell-free synthesis has been proposed to expedite peptide identification [24], but other steps of the AI-driven AMP discovery pipeline should also be accelerated.

# Acknowledgments

We would like to express our gratitude to Tomasz Grzegorzek, Adam Izdebski, Michał Michalski, and Marcin Możejko for insightful discussions on the subject of AMP discovery.

## References

- [1] C. J. Murray, K. S. Ikuta, F. Sharara, L. Swetschinski, G. Robles Aguilar, A. Gray, C. Han, C. Bisignano, P. Rao, E. Wool, S. C. Johnson, A. J. Browne, M. G. Chipeta, F. Fell, S. Hackett, G. Haines-Woodhouse, B. H. Kashef Hamadani, E. A. P. Kumaran, B. McManigal, R. Agarwal, S. Akech, S. Albertson, J. Amuasi, J. Andrews, A. Aravkin, E. Ashley, F. Bailey, S. Baker, B. Basnyat, A. Bekker, R. Bender, A. Bethou, J. Bielicki, S. Boonkasidecha, J. Bukosia, C. Carvalheiro, C. Castañeda-Orjuela, V. Chansamouth, S. Chaurasia, S. Chiurchiù, F. Chowdhury, A. J. Cook, B. Cooper, T. R. Cressey, E. Criollo-Mora, M. Cunningham, S. Darboe, N. P. J. Day, M. De Luca, K. Dokova, A. Dramowski, S. J. Dunachie, T. Eckmanns, D. Eibach, A. Emami, N. Feasey, N. Fisher-Pearson, K. Forrest, D. Garrett, P. Gastmeier, A. Z. Giref, R. C. Greer, V. Gupta, S. Haller, A. Haselbeck, S. I. Hay, M. Holm, S. Hopkins, K. C. Iregbu, J. Jacobs, D. Jarovsky, F. Javanmardi, M. Khorana, N. Kissoon, E. Kobeissi, T. Kostyanev, F. Krapp, R. Krumkamp, A. Kumar, H. H. Kyu, C. Lim, D. Limmathurotsakul, M. J. Loftus, M. Lunn, J. Ma, N. Mturi, T. Munera-Huertas, P. Musicha, M. M. Mussi-Pinhata, T. Nakamura, R. Nanavati, S. Nangia, P. Newton, C. Ngoun, A. Novotney, D. Nwakanma, C. W. Obiero, A. Olivas-Martinez, P. Olliaro, E. Ooko, E. Ortiz-Brizuela, A. Y. Peleg, C. Perrone, N. Plakkal, A. Ponce-de Leon, M. Raad, T. Ramdin, A. Riddell, T. Roberts, J. V. Robotham, A. Roca, K. E. Rudd, N. Russell, J. Schnall, J. A. G. Scott, M. Shivamallappa, J. Sifuentes-Osornio, N. Steenkeste, A. J. Stewardson, T. Stoeva, N. Tasak, A. Thaiprakong, G. Thwaites, C. Turner, P. Turner, H. R. van Doorn, S. Velaphi, A. Vongpradith, H. Vu, T. Walsh, S. Waner, T. Wangrangsimakul, T. Wozniak, P. Zheng, B. Sartorius, A. D. Lopez, A. Stergachis, C. Moore, C. Dolecek, and M. Naghavi, "Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis," The Lancet, vol. 399, pp. 629–655, Feb. 2022.
- [2] M. Miethke, M. Pieroni, T. Weber, M. Brönstrup, P. Hammann, L. Halby, P. B. Arimondo, P. Glaser, B. Aigle, H. B. Bode, *et al.*, "Towards the sustainable discovery and development of new antibiotics," *Nature Reviews Chemistry*, vol. 5, no. 10, pp. 726–749, 2021.
- [3] Y. Zhu, W. Hao, X. Wang, J. Ouyang, X. Deng, H. Yu, and Y. Wang, "Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug-resistant infections," *Medicinal Research Reviews*, vol. 42, no. 4, pp. 1377–1422, 2022.
- [4] G. Shi, X. Kang, F. Dong, Y. Liu, N. Zhu, Y. Hu, H. Xu, X. Lao, and H. Zheng, "DRAMP 3.0: an enhanced comprehensive data repository of antimicrobial peptides," *Nucleic Acids Research*, vol. 50, pp. D488–D496, Jan. 2022.
- [5] J. V. Carratalá, N. Serna, A. Villaverde, E. Vázquez, and N. Ferrer-Miralles, "Nanostructured antimicrobial peptides: The last push towards clinics," *Biotechnology Advances*, vol. 44, p. 107603, Nov. 2020.
- [6] M. Magana, M. Pushpanathan, A. L. Santos, L. Leanse, M. Fernandez, A. Ioannidis, M. A. Giulianotti, Y. Apidianakis, S. Bradfute, A. L. Ferguson, and others, "The value of antimicrobial peptides in the age of resistance," *The Lancet Infectious Diseases*, 2020. Publisher: Elsevier.
- [7] F. Grisoni, "Chemical language models for de novo drug design: Challenges and opportunities," Current Opinion in Structural Biology, vol. 79, p. 102527, Apr. 2023.
- [8] A. Strokach and P. M. Kim, "Deep generative modeling for protein design," Current Opinion in Structural Biology, vol. 72, pp. 226–236, Feb. 2022.
- [9] M. C. Melo, J. R. Maasch, and C. de la Fuente-Nunez, "Accelerating antibiotic discovery through artificial intelligence," *Communications biology*, vol. 4, no. 1, p. 1050, 2021.
- [10] C. H. Chen, T. Bepler, K. Pepper, D. Fu, and T. K. Lu, "Synthetic molecular evolution of antimicrobial peptides," *Current opinion in biotechnology*, vol. 75, p. 102718, 2022.
- [11] F. C. Fernandes, M. H. Cardoso, A. Gil-Ley, L. V. Luchi, M. G. da Silva, M. L. Macedo, C. de la Fuente-Nunez, and O. L. Franco, "Geometric deep learning as a potential tool for antimicrobial peptide prediction," *Frontiers in Bioinformatics*, vol. 3, 2023.

- [12] F. Wan, D. Kontogiorgos-Heintz, and C. de la Fuente-Nunez, "Deep generative models for peptide design," *Digital Discovery*, vol. 1, no. 3, pp. 195–208, 2022.
- [13] Clinical and L. S. I. (CLSI), "Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—ninth edition; document m07-a8," 2012.
- [14] M. R. Loffredo, F. Savini, S. Bobone, B. Casciaro, H. Franzyk, M. L. Mangoni, and L. Stella, "Inoculum effect of antimicrobial peptides," *Proceedings of the National Academy of Sciences*, vol. 118, no. 21, p. e2014364118, 2021.
- [15] P. G. Aronica, L. M. Reid, N. Desai, J. Li, S. J. Fox, S. Yadahalli, J. W. Essex, and C. S. Verma, "Computational methods and tools in antimicrobial peptide research," *Journal of Chemical Information* and Modeling, vol. 61, no. 7, pp. 3172–3196, 2021.
- [16] M. Pirtskhalava, A. A. Amstrong, M. Grigolava, M. Chubinidze, E. Alimbarashvili, B. Vishnepolsky, A. Gabrielian, A. Rosenthal, D. E. Hurt, and M. Tartakovsky, "DBAASP v3: database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics," *Nucleic acids research*, vol. 49, no. D1, pp. D288–D297, 2021.
- [17] C. Li, D. Sutherland, S. A. Hammond, C. Yang, F. Taho, L. Bergman, S. Houston, R. L. Warren, T. Wong, L. Hoang, *et al.*, "AMPlify: attentive deep learning model for discovery of novel antimicrobial peptides effective against who priority pathogens," *BMC genomics*, vol. 23, no. 1, pp. 1–15, 2022.
- [18] M. Ghorbani, S. Prasad, B. R. Brooks, and J. B. Klauda, "Deep attention based variational autoencoder for antimicrobial peptide discovery," *bioRxiv*, pp. 2022–07, 2022.
- [19] J. B. Ferrell, J. M. Remington, C. M. Van Oort, M. Sharafi, R. Aboushousha, Y. Janssen-Heininger, S. T. Schneebeli, M. J. Wargo, S. Wshah, and J. Li, "A generative approach toward precision antimicrobial peptide design," *BioRxiv*, pp. 2020–10, 2020.
- [20] P. Das, T. Sercu, K. Wadhawan, I. Padhi, S. Gehrmann, F. Cipcigan, V. Chenthamarakshan, H. Strobelt, C. Dos Santos, P.-Y. Chen, et al., "Accelerated antimicrobial discovery via deep generative models and molecular dynamics simulations," *Nature Biomedical Engineering*, vol. 5, no. 6, pp. 613–623, 2021.
- [21] C. M. Van Oort, J. B. Ferrell, J. M. Remington, S. Wshah, and J. Li, "AMPGAN v2: machine learningguided design of antimicrobial peptides," *Journal of chemical information and modeling*, vol. 61, no. 5, pp. 2198–2207, 2021.
- [22] S. Renaud and R. A. Mansbach, "Latent spaces for antimicrobial peptide design," *Digital Discovery*, vol. 2, no. 2, pp. 441–458, 2023.
  \* This paper proposes metrics for the hard task of comparison and evaluation of generative models with latent spaces, and proposes interpretable method of latent space sampling using PCA.
- [23] M. Ansari and A. D. White, "Learning peptide properties with positive examples only," *bioRxiv*, pp. 2023–06, 2023.
- [24] A. Pandi, D. Adam, A. Zare, V. T. Trinh, S. L. Schaefer, M. Wiegand, B. Klabunde, E. Bobkova, M. Kushwaha, Y. Foroughijabbari, *et al.*, "Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides," *BioRxiv*, pp. 2022–11, 2022. **\*\* This work couples generative modelling via VAE with fast screening of candidates to efficiently obtain highly active peptides.**
- [25] L. Losin and D. Veltri, "Exploring target specificity of antimicrobial peptides through deep learning embeddings," in *Proceedings of the 12th ACM Conference on Bioinformatics, Computational Biology,* and Health Informatics, pp. 1–1, 2021.
- [26] M. J. Buehler, "Generative pretrained autoregressive transformer graph neural network applied to the analysis and discovery of novel proteins," arXiv preprint arXiv:2305.04934, 2023.

- [27] J. Huang, Y. Xu, Y. Xue, Y. Huang, X. Li, X. Chen, Y. Xu, D. Zhang, P. Zhang, J. Zhao, et al., "Identification of potent antimicrobial peptides via a machine-learning pipeline that mines the entire space of peptide sequences," *Nature Biomedical Engineering*, pp. 1–14, 2023.
- [28] A. Capecchi, X. Cai, H. Personne, T. Köhler, C. van Delden, and J.-L. Reymond, "Machine learning designs non-hemolytic antimicrobial peptides," *Chemical science*, vol. 12, no. 26, pp. 9221–9232, 2021.
- [29] S. Surana, P. Arora, D. Singh, D. Sahasrabuddhe, and J. Valadi, "PandoraGAN: generating antiviral peptides using generative adversarial network," *bioRxiv*, pp. 2021–02, 2021.
- [30] S. N. Dean, J. A. E. Alvarez, D. Zabetakis, S. A. Walper, and A. P. Malanoski, "PepVAE: variational autoencoder framework for antimicrobial peptide generation and activity prediction," *Frontiers in mi*crobiology, vol. 12, p. 725727, 2021.
- [31] P. Szymczak, M. Możejko, T. Grzegorzek, R. Jurczak, M. Bauer, D. Neubauer, K. Sikora, M. Michalski, J. Sroka, P. Setny, et al., "Discovering highly potent antimicrobial peptides with deep generative model HydrAMP," Nature Communications, vol. 14, no. 1, p. 1453, 2023.
  \*\* HydrAMP is a cVAE-based model, which is specifically trained to perform analogue generation both from positives and negatives, as well as unconstrained generation. The model disentangles the learnt representation of a peptide from its antimicrobial conditions and leverages parameter-controlled creativity.
- [32] A. Tucs, F. Berenger, A. Yumoto, R. Tamura, T. Uzawa, and K. Tsuda, "Quantum annealing designs nonhemolytic antimicrobial peptides in a discrete latent space," ACS Medicinal Chemistry Letters, vol. 14, no. 5, pp. 577–582, 2023.
  \*\* Tučs et al. combine binary VAE with quantum annealing to obtain peptides with both high activity and low toxicity, explicitly adressing the Pareto optimization problem.
- [33] R. Sharma, S. Shrivastava, S. K. Singh, A. Kumar, A. K. Singh, and S. Saxena, "EnDL-HemoLyt: Ensemble deep learning-based tool for identifying therapeutic peptides with low hemolytic activity," *IEEE Journal of Biomedical and Health Informatics*, 2023.
- [34] H. Teimouri, A. Medvedeva, and A. B. Kolomeisky, "Bacteria-specific feature selection for enhanced antimicrobial peptide activity predictions using machine-learning methods," *Journal of Chemical Information and Modeling*, vol. 63, no. 6, pp. 1723–1733, 2023.
- [35] B. Vishnepolsky, M. Grigolava, G. Managadze, A. Gabrielian, A. Rosenthal, D. E. Hurt, M. Tartakovsky, and M. Pirtskhalava, "Comparative analysis of machine learning algorithms on the microbial strain-specific amp prediction," *Briefings in Bioinformatics*, vol. 23, no. 4, p. bbac233, 2022.
  \* Vishnepolsky et al. leverage genomic features in a multi-strain specific MIC prediction method.
- [36] J. Yan, B. Zhang, M. Zhou, F.-X. Campbell-Valois, and S. W. Siu, "A deep learning method for predicting the minimum inhibitory concentration of antimicrobial peptides against escherichia coli using multibranch-cnn and attention," 2023.
- [37] A. Chharia, R. Upadhyay, and V. Kumar, "Novel fuzzy approach to antimicrobial peptide activity prediction: A tale of limited and imbalanced data that models won't hear," in *NeurIPS 2021 AI for Science Workshop*, 2021.
- [38] B. Olcay, G. D. Ozdemir, M. A. Ozdemir, U. K. Ercan, O. Guren, and O. Karaman, "Prediction of the synergistic effect of antimicrobial peptides and antibiotics via supervised machine learning technique," 2022.
- [39] W. F. Porto, K. C. Ferreira, S. M. Ribeiro, and O. L. Franco, "Sense the moment: A highly sensitive antimicrobial activity predictor based on hydrophobic moment," *Biochimica et Biophysica Acta (BBA)-General Subjects*, vol. 1866, no. 3, p. 130070, 2022.

- [40] S. Yang, Z. Yang, and X. Ni, "AMPFinder: A computational model to identify antimicrobial peptides and their functions based on sequence-derived information," *Analytical Biochemistry*, vol. 673, p. 115196, 2023.
- [41] D. Wang, Z. Wen, F. Ye, H. Zhou, and L. Li, "Accelerating antimicrobial peptide discovery with latent sequence-structure model," arXiv preprint arXiv:2212.09450, 2022.
- [42] Y. Murakami, S. Ishida, Y. Demizu, and K. Terayama, "Design of antimicrobial peptides containing non-proteinogenic amino acids using multi-objective bayesian optimisation," *Digital Discovery*, pp. -, 2023.
   \* This would be accelerated to prove a state of the protein state.

\* This model is specifically tailored to recommend candidates with non-proteinogenic amino-acids. This is achieved via Bayesian Optimization with Gaussian process-based surrogate models. Each peptide is assigned a score computed as a product of a probability of improvement of antimicrobial activities against six strains of bacteria and hemolicity.

- [43] P. Pandey and A. Srivastava, "sAMP-VGG16: Drude polarizable force-field assisted image-based deep neural network prediction model for short antimicrobial peptides," *bioRxiv*, pp. 2023–06, 2023.
- [44] H. Lee, S. Lee, I. Lee, and H. Nam, "AMP-BERT: Prediction of antimicrobial peptide function based on a BERT model," *Protein Science*, vol. 32, no. 1, p. e4529, 2023.
- [45] Q. Cao, C. Ge, X. Wang, P. J. Harvey, Z. Zhang, Y. Ma, X. Wang, X. Jia, M. Mobli, D. J. Craik, et al., "Designing antimicrobial peptides using deep learning and molecular dynamic simulations," *Briefings in Bioinformatics*, vol. 24, no. 2, p. bbad058, 2023.
- [46] R. Sharma, S. Shrivastava, S. K. Singh, A. Kumar, A. K. Singh, and S. Saxena, "Artificial intelligencebased model for predicting the minimum inhibitory concentration of antibacterial peptides against eskapee pathogens," *IEEE Journal of Biomedical and Health Informatics*, 2023.
- [47] M. Salem, A. Keshavarzi Arshadi, and J. S. Yuan, "AMPDeep: hemolytic activity prediction of antimicrobial peptides using transfer learning," *BMC bioinformatics*, vol. 23, no. 1, pp. 1–17, 2022.
- [48] Y. Jiang, R. Wang, J. Feng, J. Jin, S. Liang, Z. Li, Y. Yu, A. Ma, R. Su, Q. Zou, et al., "Explainable deep hypergraph learning modeling the peptide secondary structure prediction," *Advanced Science*, vol. 10, no. 11, p. 2206151, 2023.
- [49] Q. Yu, Z. Dong, X. Fan, L. Zong, and Y. Li, "HMD-AMP: Protein language-powered hierarchical multilabel deep forest for annotating antimicrobial peptides," arXiv preprint arXiv:2111.06023, 2021.
- [50] Y. Ma, Z. Guo, B. Xia, Y. Zhang, X. Liu, Y. Yu, N. Tang, X. Tong, M. Wang, X. Ye, et al., "Identification of antimicrobial peptides from the human gut microbiome using deep learning," *Nature Biotechnology*, vol. 40, no. 6, pp. 921–931, 2022.
- [51] Y. Liu, X. Zhang, Y. Liu, Y. Su, X. Zeng, and G. G. Yen, "Evolutionary multi-objective optimization in searching for various antimicrobial peptides [feature]," *IEEE Computational Intelligence Magazine*, vol. 18, no. 2, pp. 31–45, 2023.
- [52] M. Ansari and A. D. White, "Serverless prediction of peptide properties with recurrent neural networks," *Journal of Chemical Information and Modeling*, vol. 63, no. 8, pp. 2546–2553, 2023.
- [53] K. Sidorczuk, P. Gagat, F. Pietluch, J. Kała, D. Rafacz, L. Bakała, J. Słowik, R. Kolenda, S. Rödiger, L. C. Fingerhut, et al., "Benchmarks in antimicrobial peptide prediction are biased due to the selection of negative data," *Briefings in Bioinformatics*, vol. 23, no. 5, p. bbac343, 2022.
- [54] C. Ardino, F. Sannio, C. Pasero, L. Botta, E. Dreassi, J.-D. Docquier, and I. D'Agostino, "The impact of counterions in biological activity: case study of antibacterial alkylguanidino ureas," *Molecular Diversity*, pp. 1–11, 2022.

- [55] X. Yang, J. Jin, R. Wang, Z. Li, Y. Wang, and L. Wei, "CACPP: A contrastive learning-based siamese network to identify anticancer peptides based on sequence only," *Journal of Chemical Information and Modeling*, 2023.
- [56] X. Wu and L. Yu, "EPSOL: sequence-based protein solubility prediction using multidimensional embedding," *Bioinformatics*, vol. 37, no. 23, pp. 4314–4320, 2021.
- [57] J. Chen, S. Zheng, H. Zhao, and Y. Yang, "Structure-aware protein solubility prediction from sequence through graph convolutional network and predicted contact map," *Journal of cheminformatics*, vol. 13, no. 1, pp. 1–10, 2021.
- [58] J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. Žídek, A. Potapenko, *et al.*, "Highly accurate protein structure prediction with alphafold," *Nature*, vol. 596, no. 7873, pp. 583–589, 2021.
- [59] S. C. Hoffman, V. Chenthamarakshan, K. Wadhawan, P.-Y. Chen, and P. Das, "Optimizing molecules using efficient queries from property evaluations," *Nature Machine Intelligence*, vol. 4, no. 1, pp. 21–31, 2022.
  \*\* Hoffman et al. introduce a VAE coupled with zeroth-order optimization and gradient descent to obtain non-hemolytic peptides without compromising activity.
- [60] M. Jain, E. Bengio, A. Hernandez-Garcia, J. Rector-Brooks, B. F. Dossou, C. A. Ekbote, J. Fu, T. Zhang, M. Kilgour, D. Zhang, et al., "Biological sequence design with gflownets," in *International Conference* on Machine Learning, pp. 9786–9801, PMLR, 2022.
- [61] S. N. Dean and S. A. Walper, "Variational autoencoder for generation of antimicrobial peptides," ACS omega, vol. 5, no. 33, pp. 20746–20754, 2020.
- [62] C. Bilodeau, W. Jin, T. Jaakkola, R. Barzilay, and K. F. Jensen, "Generative models for molecular discovery: Recent advances and challenges," *Wiley Interdisciplinary Reviews: Computational Molecular Science*, vol. 12, no. 5, p. e1608, 2022.
- [63] P. Cardoso, H. Glossop, T. G. Meikle, A. Aburto-Medina, C. E. Conn, V. Sarojini, and C. Valery, "Molecular engineering of antimicrobial peptides: Microbial targets, peptide motifs and translation opportunities," *Biophysical reviews*, vol. 13, pp. 35–69, 2021.
- [64] A. B. Benjamin, M. G. Moule, M. K. Didwania, J. Hardy, P. Saenkham-Huntsinger, P. Sule, J. E. Nielsen, J. S. Lin, C. H. Contag, A. E. Barron, et al., "Efficacy of cathelicidin-mimetic antimicrobial peptoids against staphylococcus aureus," *Microbiology Spectrum*, vol. 10, no. 3, pp. e00534–22, 2022.